Orchestra BioMed shareholders elect directors, approve ESPP and auditor at 2026 annual meeting

Orchestra BioMed Holdings, Inc.

Elected Class III directors: Hochman (39.7M for), Sherman (39.5M), Fain (37.8M); no contested.
Ratified Ernst & Young as auditor for FY 2026: 49.0M for, 13,692 against.
Approved 2026 Employee Stock Purchase Plan: 39.6M for, 150,243 against.
Advisory say-on-pay approved: 38.0M for, 1.8M against, 67,523 abstain.
Advisory vote on say-on-pay frequency: 39.0M preferred 1 year; company will hold annual votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.